Table 1.
HIV-infected mothers profile.
| ID | WG (w) | ART | CD4 mm3 | CD8 mm3 | Ratio CD4/CD8 | VL copies/mL | DT (y) | NBW (g) | NBS | PW (g) | P | D | A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 37.9 | 3TC/AZT + LPV/RTV | 793 | 566 | 1.40 | <50 | – | 2,500 | F | 330 | 1 | 0 | 0 |
| 2 | 37.7 | TDF + ATV + RTV + 3TC/AZT | 345 | 760 | 0.45 | <50 | 12 | 2,750 | F | – | 4 | 3 | 0 |
| 3 | 38.1 | 3TC/AZT + RTV + LPV/RTV | 156 | 745 | 0.21 | <50 | 13 | 3,260 | F | 440 | 4 | 3 | 1 |
| 4 | 37.4 | TDF + ATV + LPV/RTV | 522 | 498 | 1.05 | <50 | 18 | 2,380 | M | 590 | 1 | 0 | 0 |
| 5 | 37.8 | 3TC/AZT + LPV/RTV | 540 | 713 | 0.76 | <50 | 2 | 2,880 | M | – | 8 | 3 | 4 |
| 6 | – | – | 243 | 310 | 0.78 | <50 | – | – | – | – | – | – | – |
| 7 | 38.3 | AZT + LPV/RTV | 392 | 662 | 0.59 | <50 | 3 | 3,070 | F | 740 | 2 | 1 | 0 |
| 8 | 37.2 | 3TC/AZT + LPV/RTV | 688 | 1,053 | 0.65 | <50 | 5 | 3,430 | F | 670 | 3 | 2 | 1 |
| 9 | 38.4 | 3TC/AZT + NVP | 666 | – | – | 1,911 | 5 | 3,420 | M | – | 4 | 0 | 3 |
| 10 | 37.3 | 3TC/AZT + LPV/RTV | 856 | 725 | 1.18 | <50 | 0 | 3,130 | M | 490 | 2 | 0 | 1 |
| 11 | – | 3TC/AZT + LPV/RTV | 1,132 | 721 | 1.57 | <50 | – | 2,820 | M | – | 2 | 1 | 0 |
| 12 | – | 3TC/AZT + LPV/RTV | 517 | 474 | 1.09 | <50 | – | 2,950 | F | – | 3 | 2 | 0 |
| 13 | 37.4 | LPV/RTV + 3TC + RAL + TDF | 327 | 734 | 0.45 | <50 | 19 | 2,600 | M | 560 | 1 | 0 | 0 |
| 14 | – | ABC + 3TC + LPV/RTV | 828 | 2,035 | 0.41 | <50 | 16 | 2,830 | F | 390 | 1 | 0 | 0 |
| 15 | 37.9 | 3TC/AZT + NVP | 656 | 1,721 | 0.38 | <50 | 1 | 2,900 | F | 500 | 3 | 1 | 1 |
| 16 | 37.6 | 3TC/AZT + LPV/RTV + TDF | 243 | 310 | 0.78 | <50 | 22 | 2,480 | M | 350 | 1 | 0 | 0 |
| 17 | 36.0 | 3TC/AZT + NVP | – | – | – | – | 7 | 2,294 | F | 810 | 3 | 0 | 2 |
| 18 | 37.7 | 3TC/AZT + LPV/RTV | 588 | – | – | <50 | 0 | 2,400 | F | 360 | 1 | 0 | 0 |
| 19 | 37.7 | AZT + 3TC + TDF | 394 | 798 | 0.49 | <50 | 13 | 2,850 | F | 500 | 5 | 2 | 2 |
| 20 | 38.2 | 3TC/AZT + LPV/RTV + TDF | 842 | 625 | 1.35 | <50 | 16 | 3,060 | M | 650 | 1 | 0 | 0 |
| 21 | 37.3 | TDF + 3TC/AZT + RAL + DRV+ RTV | 459 | 820 | 0.56 | <50 | 18 | 2,720 | F | 480 | 1 | 0 | 0 |
| 22 | 37.7 | 3TC/AZT + LPV/RTV | 326 | – | – | <50 | 0 | 3,120 | F | 760 | 3 | 2 | 0 |
| 23 | – | 3TC/AZT + NVP | 388 | 1,246 | 0.31 | <50 | – | 1,960 | M | 250 | 1 | 0 | 0 |
| 24 | 39.1 | ABC+3TC+ATV+RTV | 1,003 | – | – | <50 | 20 | 2,580 | F | 400 | 1 | 0 | 0 |
| 25 | 38.6 | TNF+3TC+RAL | 241 | – | – | 383 | 1 | 3,130 | M | 465 | 1 | 0 | 0 |
| 26 | 39 | TNF+3TC+NVP | 1,047 | – | – | <50 | – | 3,695 | M | 665 | 3 | 1 | 1 |
ID, identification number; WG, week of gestation at delivery; ART, antiretroviral therapy; VL, viral load; DT, diagnostic time; NBW, Newborn weight; NBS, Newborn sex; F, female; M, male; PW, Placenta weight; P, pregnancy; D, delivery; A, abortion; Y, years; g, grams; ART: 3TC, Lamivudine; TDF, Tenofovir; AZT, zidovudine; NVP, Nevirapine; RAL, Raltegravir; DRV, Darunavir; RTV, Ritonavir; LPV, Lopinavir; ABC, Abacavir; ATV, Atazanavir.